← back to search

Juhi R. Kuchroo

Center for Cancer Research · US
Area of research
Oncology · Immunology
Research interest
Research interests include CD8, Cell biology, Blockade, Progenitor cell, Progenitor, and Immunology.
h-index
citations
2,573
works
4
NIH funding
primary concept
email

Recent publications

B-cell-specific checkpoint molecules that regulate anti-tumour immunity
Nature 2023cited by 166position: middledoi
PD-1 restraint of regulatory T cell suppressive activity is critical for immune tolerance
The Journal of Experimental Medicine 2020cited by 254position: middledoi
Single-cell analyses identify circulating anti-tumor CD8 T cells and markers for their enrichment
The Journal of Experimental Medicine 2020cited by 124position: middledoi
Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade
Nature Immunology 2019cited by 2,029position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Arlene H. Sharpe · Harvard University2 papers (2020–2020) · 1 papers (2020–2020)Gordon J. Freeman · Harvard University1 papers (2020–2020)Jessica N. Buck · Medizinische Hochschule Hannover1 papers (2020–2020)Jason M. Schenkel · The University of Texas MD Anderson Cancer Center1 papers (2020–2020)Margaret M. Lowe · University of California, San Francisco1 papers (2020–2020)Christine G. Lian · Boston University1 papers (2020–2020)Katy K. Tsai · UCSF Helen Diller Family Comprehensive Cancer Center1 papers (2020–2020)Jaclyn M. Long · Broad Institute1 papers (2020–2020)Samantha Guinn · Johns Hopkins Medicine1 papers (2020–2020)Dan Liang · Baylor University1 papers (2020–2020) · 1 papers (2020–2020) · 1 papers (2020–2020) · 1 papers (2020–2020) · 1 papers (2020–2020)George F. Murphy · Harvard Stem Cell Institute1 papers (2020–2020)Dario A.A. Vignali · University of Pittsburgh1 papers (2020–2020) · 1 papers (2020–2020)Michael D. Rosenblum · University of California, San Francisco1 papers (2020–2020)Jacob M. Luber · The University of Texas at Arlington1 papers (2020–2020)